Loading...
Docoh

Eiger BioPharmaceuticals (EIGR)

News

From Benzinga Pro
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
11 May 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Eiger Biopharmaceuticals And AnGes Announce Exclusive Partnership For Regulatory Approval And Commercialization Of Zokinvy In Japan
10 May 22
News, Contracts
Eiger Biopharmaceuticals Inc. ((", Eiger", , NASDAQ:EIGR) and AnGes Inc. ((", AnGes", , TYO:4563) today announced that the companies entered into an agreement for the regulatory approval, marketing,
Eiger BioPharmaceuticals Q1 EPS $(0.64), Inline, Sales $2.67M Miss $4.04M Estimate
5 May 22
Earnings, News
Eiger BioPharmaceuticals (NASDAQ:EIGR) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This is a 175.29 percent decrease over earnings of $0.85 per share from the same period last
Earnings Scheduled For May 5, 2022
5 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Eiger Biopharmaceuticals Gramted U.S. Patent #11,311,519 Treatment of hepatitis delta virus infection
26 Apr 22
News
View patent here
Eiger Announces Publication Of Phase 2 Results Of Avexitide In Children With Congenital Hyperinsulinism And Initiation Of Phase 3 Program
25 Apr 22
Biotech, General
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases,
64 Biggest Movers From Yesterday
18 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co.
31 Stocks Moving In Thursday's Mid-Day Session
17 Mar 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers TD Holdings, Inc. (NASDAQ: GLG) rose 83.2% to $0.4348 after the company reported FY21 results.
Mid-Morning Market Update: Markets Edge higher; US Weekly Jobless Claims Drop To 214,000
17 Mar 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
U.S. stocks traded slightly higher this morning following the release of weekly jobless claims data on Thursday.
Why Eiger BioPharmaceuticals Stock Is Jumping Today
17 Mar 22
Biotech, News, Health Care, Movers, Trading Ideas, General
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
17 Mar 22
Pre-Market Outlook, Markets, Movers
Eiger BioPharma Reports Single Dose Of Its Lambda For COVID 'significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits greater than six hours by 50%'
17 Mar 22
Biotech, News, FDA, General
Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
17 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Eiger BioPharmaceuticals's Return On Capital Employed Overview
14 Mar 22
Earnings
According to data from Benzinga Pro, during Q4, Eiger BioPharmaceuticals's (NASDAQ:EIGR) reported sales totaled $3.36 million. Despite a 2.05% increase in earnings, the company posted a loss of $21.77 million.
95 Biggest Movers From Friday
14 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9.51.
Eiger BioPharmaceuticals: Q4 Earnings Insights
10 Mar 22
Earnings
Eiger BioPharmaceuticals (NASDAQ:EIGR) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Eiger BioPharmaceuticals reported in-line EPS of $-0.64 versus an estimate of $-0.64.
Eiger BioPharmaceuticals Q4 EPS $(0.64), Inline
10 Mar 22
Earnings, News
Eiger BioPharmaceuticals (NASDAQ:EIGR) reported quarterly losses of $(0.64) per share which met the analyst consensus estimate. This is a 10.34 percent decrease over losses of $(0.58) per share from the same period last
Earnings Scheduled For March 10, 2022
10 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
6 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, Top Stories, General
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.

Press releases

From Benzinga Pro
Eiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment Conference
16 May 22
Press Releases
PALO ALTO, Calif, May 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis
Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan
10 May 22
Press Releases
PALO ALTO, Calif. and OSAKA, Japan, May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceuticals Inc. ((", Eiger", , NASDAQ:EIGR) and AnGes Inc. ((", AnGes", , TYO:4563) today announced that the companies entered
Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
5 May 22
Earnings, Press Releases
Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year EndZokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022Phase 3
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
29 Apr 22
Press Releases
PALO ALTO, Calif., April 29, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis
Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program
25 Apr 22
Press Releases
- Phase 2 study demonstrating avexitide significantly reduced hypoglycemia in children with congenital hyperinsulinism published in Diabetes Care- Eiger plans to initiate avexitide Phase 3 registrational program by
Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5
21 Apr 22
Press Releases
- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development
Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments
18 Apr 22
Press Releases
Chris Kurtz Appointed Chief Technical OfficerSarah Mathieson Appointed Senior Vice President, Corporate AffairsPALO ALTO, Calif., April 18, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a
Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study
17 Mar 22
Press Releases
Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022
16 Mar 22
Press Releases
Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
10 Mar 22
Earnings, Press Releases
PALO ALTO, Calif., March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in
Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10
24 Feb 22
Press Releases
PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis